Phaseline

Targets › ASNS

ASNS (Asparagine synthetase [glutamine-hydrolyzing]): drug programs, companies and trials

6 programs from 6 companies in 9 trials: 4 Phase 1, 4 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.

Catalyzes the ATP-dependent synthesis of L-asparagine from L-aspartate, using L-glutamine as a source of nitrogen. Can also use ammonia as the nitrogen source in vitro. (UniProt, P08243)

Open in Phaseline: the race on ASNS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Assistance Publique - Hôpitaux de Parispegaspargase
PEGylated asparaginase depletes asparagine to induce leukemic cell death
ASNSPhase 3Acute Lymphoblastic LeukemiaMar 2027
Peking University Cancer Hospital & InstitutePegaspargase
Asparagine synthetase inhibitor (PEGylated asparaginase)
ASNSPhase 2NK/T Cell LymphomaDec 2026
Dana-Farber Cancer InstituteNeo Vax
Pegylated asparaginase (calaspargase pegol)
ASNSPhase 2Acute Lymphoblastic Leukemia; Breast Cancer Female; Follicular Lymphoma; Non-small Cell Lung CancerDec 2026
M.D. Anderson Cancer CenterCalaspargase pegol-mknl
Asparaginase analog; depletes asparagine
ASNSPhase 2T-cell Acute Lymphoblastic LeukemiaDec 2029
Mingzhi ZhangPegaspargase
PEGylated asparaginase that depletes asparagine
ASNSPhase 1NKTCLDec 2026
H. Lee Moffitt Cancer Center and Research InstituteCalaspargase Pegol
Asparaginase pegol - depletes serum asparagine
ASNSPhase 1Acute Lymphoblastic Leukemia–

Conditions

Acute Lymphoblastic Leukemia (3) T-cell Acute Lymphoblastic Leukemia (1) NK/T Cell Lymphoma (1) NKTCL (1) Breast Cancer Female (1) Follicular Lymphoma (1) Non-small Cell Lung Cancer (1)

Modalities

mixed (3), protein or peptide (2), small molecule (1)

Companies

H. Lee Moffitt Cancer Center and Research Institute (1) M.D. Anderson Cancer Center (1) Peking University Cancer Hospital & Institute (1) Mingzhi Zhang (1) Assistance Publique - Hôpitaux de Paris (1) Dana-Farber Cancer Institute (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.